Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 98 citing articles:

Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
Baoqi Zeng, Le Gao, Qingxin Zhou, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 234
The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good
Kevin Bardosh, Alexandre de Figueiredo, Rachel Gur‐Arie, et al.
BMJ Global Health (2022) Vol. 7, Iss. 5, pp. e008684-e008684
Open Access | Times Cited: 221
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310650-e2310650
Open Access | Times Cited: 175
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022
Chiara Sacco, Martina Del Manso, Alberto Mateo‐Urdiales, et al.
The Lancet (2022) Vol. 400, Iss. 10346, pp. 97-103
Open Access | Times Cited: 110
mRNA vaccines in disease prevention and treatment
Gang Zhang, Tianyu Tang, Yinfeng Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 96
A modeling study to define guidelines for antigen screening in schools and workplaces to mitigate COVID-19 outbreaks
Yong Dam Jeong, Keisuke Ejima, Kwang Su Kim, et al.
Communications Medicine (2025) Vol. 5, Iss. 1
Open Access | Times Cited: 1
Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 – February 2022)
Daniele Petrone, Alberto Mateo‐Urdiales, Chiara Sacco, et al.
International Journal of Infectious Diseases (2023) Vol. 129, pp. 135-141
Open Access | Times Cited: 34
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study
Alberto Mateo‐Urdiales, Chiara Sacco, Emmanouil Alexandros Fotakis, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1349-1359
Open Access | Times Cited: 30
SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020–31 January 2023
Luca Cegolon, Greta Camilla Magnano, Corrado Negro, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1551-1551
Open Access | Times Cited: 28
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021
Jostein Starrfelt, Anders Skyrud Danielsen, Eirik Alnes Buanes, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 33
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Raynell Lang, Elizabeth Humes, Sally B. Coburn, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2236397-e2236397
Open Access | Times Cited: 33
Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave
Cecilia Acuti Martellucci, Maria Elena Flacco, Graziella Soldato, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 662-662
Open Access | Times Cited: 32
Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data
Omar Yaxmehen Bello‐Chavolla, Neftalí Eduardo Antonio-Villa, Sergio Iván Valdés‐Ferrer, et al.
International Journal of Infectious Diseases (2023) Vol. 129, pp. 188-196
Open Access | Times Cited: 16
Understanding the time-driven shifts of vaccine effectiveness against any and severe COVID-19 before and after the surge of Omicron variants within 2.5 years of vaccination: A meta-regression
Marek Petráš, D Janovská, Danuše Lomozová, et al.
International Journal of Infectious Diseases (2024) Vol. 142, pp. 106986-106986
Open Access | Times Cited: 5
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques
Christopher T Edwards, Kirti A. Karunakaran, Elijah Garcia, et al.
PLoS Pathogens (2025) Vol. 21, Iss. 1, pp. e1012456-e1012456
Open Access
Long-Term Response to SARS-CoV-2 mRNA Vaccine in Adolescents
Mi Seon Han, Su-Jin Choi, Yoonsun Yoon, et al.
The Pediatric Infectious Disease Journal (2025)
Closed Access
Time-varying effects of COVID-19 vaccination on symptomatic and asymptomatic infections in a prospective university cohort in the USA
Lucy Robinson, Anna Feting, Isamu Isozaki, et al.
BMJ Open (2025) Vol. 15, Iss. 2, pp. e084408-e084408
Open Access
Estimating SARS‐CoV‐2 infections and associated changes in COVID‐19 severity and fatality
Valentina Marziano, Giorgio Guzzetta, Francesco Menegale, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 8
Open Access | Times Cited: 14
Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19
Alberto Mateo‐Urdiales, Chiara Sacco, Daniele Petrone, et al.
JAMA Network Open (2023) Vol. 6, Iss. 10, pp. e2336854-e2336854
Open Access | Times Cited: 12
Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study
Kim Bouillon, Bérangère Baricault, Jérémie Botton, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000104-e000104
Open Access | Times Cited: 18
Severity of Omicron Subvariants and Vaccine Impact in Catalonia, Spain
Víctor López de Rioja, Luca Basile, Aida Perramon, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 466-466
Open Access | Times Cited: 3
Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study
Pietro Ferrara, D. Ponticelli, Lorenzo Losa, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 247-247
Open Access | Times Cited: 9
SIRS epidemics with individual heterogeneity of immunity waning
Mohamed El Khalifi, Tom Britton
Journal of Theoretical Biology (2024) Vol. 587, pp. 111815-111815
Open Access | Times Cited: 2
Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022–2023
Massimo Fabiani, Alberto Mateo‐Urdiales, Chiara Sacco, et al.
Vaccine (2024) Vol. 42, Iss. 23, pp. 126026-126026
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top